Bristol-Myers Squibb News

German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount

German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concerns about the company's vulnerability to a takeover.Mul

Benzinga13:46 ET

Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2024 on Friday, July 26, 2024. Company executives will review financial results and a

BusinesswireJun 20 06:59 ET

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.

BenzingaJun 19 13:35 ET

From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data

USA News Group – This year's 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without...

PR NewswireJun 19 13:09 ET

M&A Is Back. 4 Stocks That Could Be Targets

By Jacob Sonenshine Mergers are back -- and that means opportunity for small-cap investors. Small-caps don't have a lot going for them. The Russell 2000 index has gained 0.2% this year, lagging the

Barron'sJun 19 01:30 ET

Express News | Bristol-Myers Squibb Co - Size of Board Will Increase to 11

ReutersJun 18 16:16 ET

Express News | Bristol Myers Squibb Elects Michael R. Mcmullen to Board of Directors

ReutersJun 18 16:16 ET

Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment

Immunocore Holdings (IMCR) said Tuesday it has randomized the first patient in a phase 3 clinical trial of brenetafusp in combination with nivolumab to treat first-line advanced or metastatic cutaneou

MT NewswiresJun 18 11:40 ET

This Is What Whales Are Betting On Bristol-Myers Squibb

Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb.Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 8 trades.If we consider th

BenzingaJun 18 11:17 ET

How Is Bristol-Myers Squibb's Stock Performance Compared to Other General Drug Manufacturers?

BarchartJun 18 09:14 ET

Express News | Bristol-Myers Squibb Co: Has Declared a Quarterly Dividend of Sixty Cents ($0.60) per Share

ReutersJun 18 06:59 ET

Express News | Bristol Myers Squibb Announces Dividend

ReutersJun 18 06:59 ET

Press Release: Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb Announces Dividend PRINCETON, N.J.--(BUSINESS WIRE)--June 18, 2024-- Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly divide

Dow JonesJun 18 06:59 ET

Shareholders in Bristol-Myers Squibb (NYSE:BMY) Have Lost 32%, as Stock Drops 3.2% This Past Week

Many investors define successful investing as beating the market average over the long term. But if you try your hand at stock picking, you risk returning less than the market. Unfortunately, that's

Simply Wall StJun 17 13:40 ET

Express News | Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion by 2029 as Clinical Trials Increase

ReutersJun 17 09:45 ET

EU to Require Additional Cancer Risk Labeling on CAR T Therapies

Seeking AlphaJun 14 15:55 ET

Bristol Myers Gets FDA Approval for Autyro for NTRK-positive Cancers

Seeking AlphaJun 13 17:28 ET

Express News | Bristol Myers Squibb Says FDA Granted Accelerated Approval To Augtyro (Repotrectinib) For Patients With NTRK-Positive Locally Advanced Or Metastatic Solid Tumors

BenzingaJun 13 16:48 ET

Express News | U.S. Food and Drug Administration Approves Augtyro™ (Repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (Tki), for the Treatment of Patients With Ntrk-Positive Locally Advanced or Metastatic Solid Tumors

ReutersJun 13 16:46 ET

Express News | FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With Ntrk Gene Fusion-Positive Solid Tumors

ReutersJun 13 14:04 ET